Intense burning may indicate an exaggerated local reaction. Pause treatment for 2-3 days, apply a gentle moisturizer (e.g., non-medicated emollient), and contact your prescriber if the sensation persists or worsens.
Aldara is approved for facial AK when multiple lesions are present, but application should be limited to the lesion sites only. Avoid spreading the cream onto surrounding healthy skin to minimise irritation.
Yes, but sunscreen should be applied after washing off Aldara and allowing the skin to dry. Choose a broad-spectrum product (SPF 30 or higher) and avoid irritating ingredients such as fragrance or alcohol.
Most patients notice a reduction in wart size within 4-6 weeks of consistent use. Complete clearance may require up to 16 weeks, depending on the number and size of lesions.
Concurrent use may increase skin irritation. If both are prescribed, your clinician may stagger the applications (e.g., retinoid on non-treatment days) or adjust the frequency of Aldara.
Aldara works by stimulating the local immune response, whereas podophyllotoxin is a cytotoxic agent that directly destroys wart tissue. The choice depends on lesion location, patient preference, and clinician assessment.
Aldara is not a controlled substance and does not affect workplace drug testing. However, you should inform your employer if you anticipate visible skin reactions that could impact your duties.
Patients with active eczema on the treatment site should avoid Aldara, as the medication may exacerbate dermatitis. Discuss alternative options with your healthcare provider.
Yes, but keep the sachets in your original packaging, carry a copy of the prescription, and check the destination country’s regulations regarding topical immunomodulators.
Applying more than the recommended amount may increase local inflammation and discomfort. Wash the area with mild soap and water, discontinue use, and seek medical advice if severe irritation develops.
Aldara is a brand-name medication that contains imiquimod as its sole active ingredient. It is supplied as a 5 % cream packaged in a single-use sachet. In the United Kingdom, Aldara is a prescription-only product regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The medication is classified within the skin-care therapeutic category and is used to treat specific skin lesions by modifying the local immune response.
Imiquimod is a synthetic immune response modifier that acts as an agonist of toll-like receptor 7 (TLR-7) on immune cells located in the skin. Activation of TLR-7 triggers a cascade that leads to the release of cytokines such as interferon-α, tumour-necrosis factor-α, and interleukins -6 and -12. These cytokines enhance the body’s innate and cell-mediated immunity, promoting the destruction of abnormal skin cells and virus-infected tissue.
The drug’s effect is local: after topical application, imiquimod remains largely in the treated area, providing a targeted immune stimulus without substantial systemic absorption. Onset of action usually occurs within a few days, with visible skin changes (redness, crusting) indicating the therapeutic process. Full clinical benefit often requires several weeks of consistent use.
Aldara is approved in the UK (EMA-authorized) for the following dermatological indications:
In each case, Aldara is applied to the affected area as directed by a prescriber. The medication is not indicated for use on face or genital skin that is otherwise healthy, nor for deep or infiltrative skin cancers.
Absolute contraindications
Known hypersensitivity to imiquimod or any component of the cream.
Severe immunosuppression (e.g., organ-transplant recipients on high-dose immunosuppressants).
Relative contraindications
Pregnancy - imiquimod is categorized as Category B3 in the UK; it should be avoided unless the potential benefit outweighs the risk.
Breast-feeding - limited data; caution is advised.
Active skin infections at the treatment site (bacterial, fungal, or viral) - treat the infection before starting Aldara.
Special populations
Elderly patients may experience more pronounced local skin reactions; dosing intervals may be adjusted.
Patients with hepatic or renal impairment do not require dose modification because systemic exposure is minimal.
Most reactions are mild to moderate and tend to resolve after treatment cessation or with temporary interruption of therapy.
Imiquimod’s topical nature limits systemic drug interactions, but the following considerations apply:
Patients should disclose all prescription, over-the-counter, and herbal products to their healthcare provider before initiating Aldara.
Standard regimen
Actinic keratosis: apply a thin layer once daily, five days per week (e.g., Monday-Friday) for up to 16 weeks.
Superficial basal cell carcinoma: apply once daily, five days per week, for a total of 6 weeks (may extend to 12 weeks based on response).
External genital warts: apply once daily, five days per week, for up to 16 weeks; treatment may be stopped earlier if lesions resolve.
Application instructions
Clean and gently dry the affected area before use.
Open the sachet, dispense the entire contents onto a clean fingertip, and spread a thin, even film over the lesion(s).
Wash hands thoroughly after application; avoid contact with eyes, mouth, or nose.
Missed dose
Apply the missed dose as soon as remembered if it is within 12 hours; otherwise, skip it and continue the regular schedule. Do not double-dose to make up for a missed application.
Overdose
Excessive application may increase local inflammation. If severe reactions develop (e.g., extensive ulceration), cease use and seek medical advice. There is no specific antidote; management is supportive.
Discontinuation
Treatment may be halted abruptly once the clinical target (clearance of lesions) is achieved. No tapering is required. However, patients should follow their prescriber’s guidance to monitor for recurrence.
This article provides educational information about Aldara and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
